Wageningen UR Teams with Luminex to Develop Multiplex Screening Solutions for Agro Biotechnology Market
18 March 2008 - 2:00AM
Business Wire
Wageningen University and Research Centre, a leading organization
in the field of life sciences and natural resources with focus on
healthy food production, biodiversity, and sustainable production
chains, and Luminex Corporation (NASDAQ: LMNX), the worldwide
leader in multiplexed solutions, today announced that they have
signed a licensing agreement to provide Wageningen UR access to
Luminex's xMAP� technology and the Luminex Bioscience Group�s assay
development capabilities. Under the terms of the agreement,
Wageningen UR will utilize Luminex's xMAP technology in selected
areas of Agro Biotechnology. Focus application areas are expected
to include plant pathogen detection, epidemiology, food safety, and
marker assisted plant and animal breeding programs. The demand for
fast multiplex testing, or performing multiple tests on a single
sample, continues to accelerate in Agro Biotechnology markets.
"Providing our customers with access to a proven multiplexing
solution is essential to assist specific research and development
needs and for long-term growth," said Raoul Bino, Professor Plant
Metabolomics and director of the Plant Sciences Group of Wageningen
UR. "We have selected Luminex's xMAP technology as a recognized
industry benchmark in life science research and multiplex
diagnostics applications. We look forward to working closely and
collaboratively with Luminex to benefit our respective customers."
Douglas Bryant, executive vice president and chief operating
officer at Luminex Corporation, commented, "This agreement with
Wageningen UR is a prime example of Luminex's growing emphasis on
establishing long-term partnerships and collaborations with market
leaders in segments of strategic significance to Luminex. In this
relationship with Wageningen UR, we are not only providing new
markets and customers with access to the Luminex xMAP technology,
we also are partnering with a recognized knowledge organization
with significant experience in Agro Biotechnology markets. We are
excited to have Wageningen UR on board, and look forward to
pursuing additional collaborative opportunities with them in the
future." About Luminex Corporation Luminex Corporation develops,
manufactures and markets proprietary biological testing
technologies with applications throughout the diagnostic and life
sciences industries. The Company's xMAP� multiplex solutions
include an open-architecture, multi-analyte technology platform
that delivers fast, accurate and cost-effective bioassay results to
markets as diverse as pharmaceutical drug discovery, clinical
diagnostics and biomedical research, including the genomics and
proteomics markets. The Company's xMAP technology is sold worldwide
and is already in use in leading clinical laboratories as well as
major pharmaceutical, diagnostic and biotechnology companies.
Further information on Luminex Corporation or xMAP can be obtained
at www.luminexcorp.com. About Wageningen UR Wageningen UR is a
collaboration between Wageningen University, Van Hall Larenstein
School of Higher Professional Education and the specialised former
research institutes (DLO) from the Dutch Ministry of Agriculture.
This combination of knowledge and experience enables Wageningen UR
with its�5.600 staff and more than 8.500 students to contribute
actively to solving scientific, social and commercial problems in
the field of life sciences and natural resources. Wageningen UR
approaches these national and international issues from the
perspectives of various disciplines, with an integrated approach
and in close collaboration with governments, companies, stakeholder
organisations, citizens, and other knowledge�institutions. We pay
attention to the balance between three priorities in society:
economics, culture and nature.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex Corporation News Articles